Neurobiology of Suicide

  • Tatiana FalconeEmail author
  • Migle Staniskyte
  • Fernando Espi Forcen
  • Jaime Vengoechea


Over the last 20 years, suicide rates have been increasing worldwide. Although the prognosis of suicide is complex, key psychosocial factors have been recognized to help identify identify individuals who may be at high risk. Nevertheless, a gap in research still exists between identifying high risk individuals and predicting when suicidal ideation and behavior will evlolve into a suicide attempt. The focus of this chapter is place on the most recent, relevant studies concerning the neurobiological findings in patients with suicidal behavior or after a suicide attempt. The convergence evidence for the role of the blood-brain barrier in the pathophysiology of suicide is described, as well as the role of several inflammatory markers and neurotropic factors.


Suicide Cytokines Adolescents Biomarkers Inflammation Neuroinflammation 


  1. 1.
    World Health Organization. Preventing suicide: a global imperative. 2014.
  2. 2.
    Nock MK, Green JG, Hwang I, McLaughlin KA, Sampson NA, Zaslavsky AM, et al. Prevalence, correlates, and treatment of lifetime suicidal behavior among adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement. JAMA Psychiat. 2013;70(3):300–10. Scholar
  3. 3.
    Centers for Disease Control and Prevention. Web-based injury statistics query and reporting system (WISQARS).
  4. 4.
    Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999;56(7):617–26. Scholar
  5. 5.
    Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127–31. Scholar
  6. 6.
    Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J Clin Psychiatry. 2003;64(1):14–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Maris RW. Suicide. Lancet. 2002;360:319–26.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Glenn CR, Nock MK. Improving the short-term prediction of suicidal behavior. Am J Prev Med. 2014;47:S176–80.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Borges G, Nock MK, Haro Abad JM, Hwang I, Sampson NA, Alonso J, et al. Twelve-month prevalence of and risk factors for suicide attempts in the World Health Organization World Mental Health surveys. J Clin Psychiatry. 2010;71(12):1617–28.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tran T, Luo W, Phung D, Harvey R, Berk M, Kennedy RL, et al. Risk stratification using data from electronic medical records better predicts suicide risks than clinician assessments. BMC Psychiatry. 2014;14(1):76.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmcol. 2002;5(4):375–88.CrossRefGoogle Scholar
  12. 12.
    Caplan R, Siddarth P, Gurbani S, Hanson R, Sankar R, Shields WD. Depression and anxiety disorders in pediatric epilepsy. Epilepsia. 2005;46(5):720–30.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pompili M, Girardi P, Ruberto A, Tatarelli R. Suicide in the epilepsies: a meta-analytic investigation of 29 cohorts. Epilepsy Behav. 2005;7(2):305–10.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ackerman JP, McBee-Strayer SM, Mendoza K, Stevens J, Sheftall AH, Campo JV, et al. Risk-sensitive decision-making deficit in adolescent suicide attempters. J Child Adolesc Psychopharmacol. 2015;25(2):109–13.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ekinci O, Titus JB, Rodopman AA, Berkem M, Trevathan E. Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. Epilepsy Behav. 2009;14(1):8–18.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Asarnow JR, Porta G, Spirito A, Emslie G, Clarke G, Wagner KD, et al. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry. 2011;50(8):772–81.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990;147(9):1189–94.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Miranda R, Shaffer D. Understanding the suicidal moment in adolescence. Ann N Y Acad Sci. 2013;1304:14–21.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Husky MM, Olfson M, He J, Nock MK, Swanson SA, Merikangas KR. Twelve-month suicidal symptoms and use of services among adolescents: results from the National Comorbidity Survey. Psych Serv. 2012;63(10):989–96.CrossRefGoogle Scholar
  20. 20.
    Costanza A, D’Orta I, Perroud N, Burkhardt S, Malafosse A, Mangin P, et al. Neurobiology of suicide: do biomarkers exist? Int J Legal Med. 2014;128(1):73–82.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH, Sublette ME, et al. Toward a biosignature for suicide. Am J Psychiatry. 2014;171(12):1259–77.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry. 1976;33(10):1193–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chatzittofis A, Nordstrom P, Hellstrom C, Arver S, Asberg M, Jokinen J. CSF 5-HIAA, cortisol and DHEAS levels in suicide attempters. Eur Neuropsychopharmacol. 2013;23(10):1280–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Courtet P, Picot MC, Bellivier F, Torres S, Jollant F, Michelon C, et al. Serotonin transporter gene may be involved in short-term risk of subsequent suicide attempts. Biol Psychiatry. 2014;55(1):46–51.CrossRefGoogle Scholar
  25. 25.
    Bellivier F, Chaste P, Malafosse A. Association between the TPH gene A218C polymorphism and suicidal behavior: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2004;124B(1):87–91.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Li D, He L. Meta-analysis supports association between serotonin transporter (5-HTT) and suicidal behavior. Mol Psychiatry. 2007;12(1):47–54.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Diaz Granados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–11.CrossRefGoogle Scholar
  29. 29.
    Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–46.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    McCrory E, De Brito SA, Viding E. Research review: the neurobiology and genetics of maltreatment and adversity. J Child Psychol Psychiatry. 2010;51(10):1079–95.CrossRefPubMedGoogle Scholar
  31. 31.
    McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12(3):342–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dwivedi Y. Brain-derived neurotrophic factor and suicide pathogenesis. Ann Med. 2010;42(2):87–96.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Deveci A, Aydemir O, Taskin O, Taneli F, Esen-Danaci A. Serum BDNF levels in suicide attempters related to psychosocial stressors: a comparative study with depression. Neuropsychobiology. 2007;56(2–3):93–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Nordström P, Samuelsson M, Åsberg M, Träskman-Bendz L, Åberg-Wistedt A, Nordin C, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav. 1994;24(1):1–9.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Angst J, Degonda M, Ernst C. The Zurich Study: XV. Suicide attempts in a cohort from age 20 to 30. Eur Arch Psychiatry Clin Neurosci. 1992;242:135–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Samuelsson M, Jokinen J, Nordström AL, Nordström P. CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatr Scand. 2006;113(1):44–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Tyano S, Zalsman G, Ofek H, Blum I, Apter A, Wolovik L, Sher L, Sommerfeld E, Harell D, Weizman A. Plasma serotonin levels and suicidal behavior in adolescents. Eur Neuropsychopharmacol. 2006;16(1):49–57.CrossRefPubMedGoogle Scholar
  38. 38.
    Mann JJ. A current perspective of suicide and attempted suicide. Ann Intern Med. 2002;136:302–11.CrossRefPubMedGoogle Scholar
  39. 39.
    Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry. 2006;11:336–51.CrossRefPubMedGoogle Scholar
  40. 40.
    Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;1:214–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry. 2000;57:729–38.CrossRefPubMedGoogle Scholar
  42. 42.
    Malone KM, Corbitt EM, Li S, Mann JJ. Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry. 1996;168:324–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Mann JJ. The neurobiology of suicide. Nat Med. 1988;4:25–30.CrossRefGoogle Scholar
  44. 44.
    Van Heeringen K. The neurobiology of suicide and suicidality. Can J Psychiatr. 2003;48:292–300.CrossRefGoogle Scholar
  45. 45.
    Mann JJ, Malone KM, Sweeney JA, Brown RP, Linnoila M, Stanley B, et al. Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients. Neuropsychopharmacology. 1996;15(6):576–86.CrossRefPubMedGoogle Scholar
  46. 46.
    Coccaro EF, Berman ME, Kavoussi RJ, Hauger RL. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men. Biol Psychiatry. 1996;40:157–64.CrossRefPubMedGoogle Scholar
  47. 47.
    O’Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry. 1991;148:1009–15.CrossRefPubMedGoogle Scholar
  48. 48.
    Escribá PV, Ozaita A, García-Sevilla JA. Increased mRNA expression of [alpha] 2A-Adrenoceptors, serotonin receptors and [mu]-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29(8):1512.CrossRefPubMedGoogle Scholar
  49. 49.
    Ordway GA, Widdowson PS, Smith KS, Halaris A. Agonist binding to α2-Adrenoceptors is elevated in the Locus Coeruleus from victims of suicide. J Neurochemistry. 1994;63(2):617–24.CrossRefGoogle Scholar
  50. 50.
    Joiner TE Jr, Brown JS, Wingate LR. The psychology and neurobiology of suicidal behavior. Annu Rev Psychol. 2005;56:287–314.CrossRefPubMedGoogle Scholar
  51. 51.
    Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry. 2001;50(10):783–91.CrossRefPubMedGoogle Scholar
  52. 52.
    Arango V, Underwood MD, Mann JJ. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry. 1996;39:112–20.CrossRefPubMedGoogle Scholar
  53. 53.
    Mann JJ, Arango V. The neurobiology of suicidal behavior. In: Jacobs DG, editor. The Harvard Medical School guide to suicide assessment and intervention. San Francisco: Jossey-Bass; 1999.Google Scholar
  54. 54.
    Mann JJ. Neurobiology of suicidal behavior. Nature. Rev Neurosci. 2003;4:819–28.CrossRefGoogle Scholar
  55. 55.
    Valdizán EM, Díez-Alarcia R, González-Maeso J, Pilar-Cuéllar F, García-Sevilla JA, Meana JJ, et al. α2-adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims. Biol Psychiatry. 2010;68:869–72.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Arranz B, Blennow K, Eriksson A, Maånsson JE, Marcusson J. Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. Biol Psychiatry. 1997;41(10):1000–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Allard P, Norlén M. Caudate nucleus dopamine D2 receptors in depressed suicide victims. Neuropsychobiology. 2001;44(2):70–3.CrossRefPubMedGoogle Scholar
  58. 58.
    Ernst C, Mechawar N, Turecki G. Suicide neurobiology. Prog Neurobiol. 2009;89:315–33.CrossRefPubMedGoogle Scholar
  59. 59.
    Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, Garcia-Sevilla JA, Guimon J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of [alpha] 2A-adrenoceptors. Mol Psychiatry. 2002;7(7):755–67.CrossRefPubMedGoogle Scholar
  60. 60.
    Wong ML, Dong C, MaestreMesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry. 2008;13:800–12.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry. 2009;65(9):760.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389:856–60.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Bartrup JT, Moorman JM, Newberry NR. BDNF enhances neuronal growth and synaptic activity in hippocampal cell cultures. Neuroreport. 1997;8:3791–4.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Thoenen H. Neurotrophins and neuronal plasticity. Science. 1995;270:593–8.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Turecki G, Ernst C, Jollant F, Labonté B, Mechawar N. The neurodevelopmental origins of suicidal behavior. Trends Neurosci. 2012;35:14–23.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–47.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Nibuya M, Nestler EJ, Duman RS. Chronic anti-depressant administration increases the expression of cAMP response element-binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365–72.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260–5.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(8):804–15. Scholar
  72. 72.
    Dwivedi Y, Mondal AC, Rizavi HS, Conley RR. Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry. 2005;58:315–24.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y. Brain-derived neurotrophic factor and tyrosine kinase B receptor signaling in postmortem brain of teenage suicide victims. Int J Neuropsychopharmacol. 2008;11:1047–61.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Pandey GN. Biological basis of suicide and suicidal behavior. Bipolar Disord. 2013;15:524–41.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Serafini G, Pompili M, Elena Seretti M, Stefani H, Palermo M, Coryell W, et al. The role of inflammatory cytokines in suicidal behavior: a systematic review. Eur Neuropsychopharmacol. 2013;23(12):1672–86.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Janelidze S, Brundin L. Inflammation in suicidality: implications for novel treatment options. Mod Trends Pharmacopsychiatri. 2013;28:188–202.CrossRefGoogle Scholar
  77. 77.
    Capuron L, Miller A, Irwin MR. Psychoneuroimmunology of depressive disorder: mechanisms and clinical implications. Psychoneuro. 2007;1:509–30.CrossRefGoogle Scholar
  78. 78.
    Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15(3):199–226. Scholar
  79. 79.
    Falcone T, Fazio V, Lee C, Simon B, Franco K, Marchi N, et al. Serum S100B: a potential biomarker for suicidality in adolescents? PLoS One. 2010;5(6):e11089. Scholar
  80. 80.
    Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25(2):335–9. Scholar
  81. 81.
    Slopen N, Koenen KC, Kubzansky LD. Childhood adversity and immune and inflammatory biomarkers associated with cardiovascular risk in youth: a systematic review. Brain Behav Immun. 2012;26(2):239–50.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull. 2004;130(4):601–30. Scholar
  83. 83.
    Singareddy R, Krishnamurthy VB, Vgontzas AN, Fernandez-Mendoza J, Calhoun SL, Shaffer ML, et al. Subjective and objective sleep and self-harm behaviors in young children: a general population study. Psychiatry Res. 2013;209(3):549–53.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Bremner JD. Does stress damage the brain? Biol Psychiatry. 1999;45(7):797–805.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Lucas M, O’Reilly EJ, Mirzaei F, Okereke OI, Unger L, Miller M, et al. Cigarette smoking and completed suicide: results from 3 prospective cohorts of American adults. J Affect Disord. 2013;151(3):1053–8. Scholar
  86. 86.
    Young SN. Elevated incidence of suicide in people living at altitude, smokers and patients with chronic obstructive pulmonary disease and asthma: possible role of hypoxia causing decreased serotonin synthesis. J Psychiatry Neurosci. 2013;38(5):130002. CrossRefGoogle Scholar
  87. 87.
    Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia. 2012;53(Suppl 1):26–34.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Janigro D. Blood-brain barrier, ion homeostasis and epilepsy: possible implications towards the understanding of ketogenic diet mechanisms. Epilepsy Res. 1999;37(3):223–32.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia. 2006;47(11):1761–74. Scholar
  90. 90.
    Serafini G, Girardi P, Erbuto D, Lester D, Pompili M. HPA axis and prolactin abnormalities in suicidal behavior. In: Pompili M, editor. Suicide: a global perspective; 2013. p. 246–53.Google Scholar
  91. 91.
    Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med. 2005;67(2):187–94. Scholar
  92. 92.
    Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al. Inflammatory markers in major depression and melancholia. J Affect Disord. 2001;63(1–3):93–102.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151–7. Scholar
  94. 94.
    Steiner J, Gos T, Bogerts B, Bielau H, Drexhage HA, Bernstein HG. Possible impact of microglial cells and the monocyte-macrophage system on suicidal behavior. CNS Neurol Disord Drug Targets. 2013;12(7):971–9.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Pandey GN, Dwivedi Y. Neurobiology of teenage suicide. In: Dwivedi Y, editor. The neurobiological basis of suicide. Boca Raton: Taylor & Francis; 2012.Google Scholar
  96. 96.
    Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res. 2012;46(1):57–63. Scholar
  97. 97.
    Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, et al. Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(1):78–85.CrossRefGoogle Scholar
  98. 98.
    Isung J, Mobarrez F, Nordstrom P, Asberg M, Jokinen J. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry. 2012;13(6):468–73.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Rothermundt M, Arolt V. Schizophrenia and immunity. In: Ader R, editor. Psychoneuroimmunology. 4th ed. Boston: Elsevier; 2007. p. 563–77.CrossRefGoogle Scholar
  100. 100.
    Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol. 1996;48(5):503–6.PubMedGoogle Scholar
  101. 101.
    Himmerich H, Fulda S, Sheldrick A, Plumakers B, Rink L. IFN gamma reduction by tricyclic antidepressants. Int J Psychiatry Med. 2011;40(4): 413–24.
  102. 102.
    Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun. 2012;26(6):979–87. Scholar
  103. 103.
    Mitchell RH, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry. 2014;53(3):274–96.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Claes S, Myint AM, Domschke K, Del-Favero J, Entrich K, Engelborghs S, et al. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res. 2011;188(3):355–60.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Miura H, Ozaki N, Sawada M, Isobe K, Ohta T, Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress. 2008;11(3):198–209.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun. 2011;25(6):1272–8. Scholar
  107. 107.
    Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743–52. Scholar
  108. 108.
    Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol. 2003;13(4):235–9.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41(6):523–9. Scholar
  110. 110.
    Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta. 2004;342(1–2):1–12. Scholar
  111. 111.
    Bruce N, Janigro D, Fazio V, Franco K, Falcone T. S100B as a tool for risk assessment in suicidal youth. Proceedings of the American Academy of Child & Adolescent Psychiatry 57th Annual Meeting; 2010; New York.Google Scholar
  112. 112.
    Li Z, Qi D, Chen J, Zhang C, Yi Z, Yuan C, et al. Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-alpha) in the Chinese patients with major depressive disorder: a prospective longitudinal study. Psychoneuroendocrinology. 2013;38(1):107–14.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Boehm J, Fischer K, Bohnert M. Putative role of TNF-alpha, interleukin-8 and ICAM-1 as indicators of an early inflammatory reaction after burn: a morphological and immunohistochemical study of lung tissue of fire victims. J Clin Pathol. 2010;63(11):967–71. Scholar
  114. 114.
    Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setala-Soikkeli E, et al. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett. 2010;477(3):105–8. Scholar
  115. 115.
    Isung J, Aeinehband S, Mobarrez F, Martensson B, Nordstrom P, Asberg M, et al. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Transl Psychiatry. 2012;2:e196. Scholar
  116. 116.
    Serafini G, Pompili M, Lindqvist D, Dwivedi Y, Girardi P. The role of neuropeptides in suicidal behavior: a systematic review. Biomed Res Int. 2013;2013:687575. Scholar
  117. 117.
    Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 2005;136(1–2):29–37. Scholar
  118. 118.
    Marchi N, Granata T, Ghosh C, Janigro D. Blood–brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia. 2012;53(11):1877–86.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Karassa FB, Magliano M, Isenberg DA. Suicide attempts in patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62(1):58–60.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J Nerv Ment Dis. 2009;3(12):905–8.CrossRefGoogle Scholar
  121. 121.
    Okusaga O, Langenberg P, Sleemi A, Vaswani D, Giegling I, Hartmann AM, et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophrenia Res. 2011;133(1):150–5.CrossRefGoogle Scholar
  122. 122.
    Zhang Y, Träskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N, et al. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. J Clin Psychiatry. 2012;73(8):1069–76.CrossRefPubMedPubMedCentralGoogle Scholar
  123. 123.
    Brundin L, Erhardt S, Bryleva EY, Achtyes ED, Postolache TT. The role of inflammation in suicidal behaviour. Acta Psychiatrica. Scandinavica. 2015;132(3):192–203.Google Scholar
  124. 124.
    Cook AJ, Holliman R, Gilbert RE, Buffolano W, Zufferey J, Petersen E, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. BMJ. 2000;321(7254):142–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Tatiana Falcone
    • 1
    Email author
  • Migle Staniskyte
    • 2
  • Fernando Espi Forcen
    • 3
  • Jaime Vengoechea
    • 4
  1. 1.Epilepsy Center/Psychiatry DepartmentNeurological Institute - Cleveland ClinicClevelandUSA
  2. 2.Neurologic Institute, Cleveland ClinicClevelandUSA
  3. 3.Department of PsychiatryRush University Medical CenterChicagoUSA
  4. 4.Pontificia Universidad JaverianaBogotaColombia

Personalised recommendations